This medicine can be habit-forming. Do not use more than your prescribed dose. Call your doctor if you think your medicine is not working. If you take this medicine every night, you might have side effects for a few days when you stop using it. Tell your doctor if you develop any unusual thoughts or behaviors. This includes aggressive behavior, confusion, hallucinations, anxiety, depression, or thoughts of hurting yourself. Call your doctor if you still have trouble sleeping after using this medicine for 7 to 10 days.

With the ZOLPIDEM Discount Card, all patients are eligible to:

  • Save up to 95% off out-of-pocket costs*
  • Pay as little as $9 each month for your 30-ct prescription**
  • Reuse this coupon card – it never expires
Print Your Pre-activated Discount Card Today!
Show the pharmacist this card from your phone or tablet.
ZOLPIDEM Prescription Discount Card

*Offer Details:

  • This Discount Card is not health insurance and cannot be used to lower your co-pay. The discount card price may be lower than your health insurance co-pay. Ask your pharmacist to help you find the best possible price.
  • This coupon card cannot be used in conjunction with any federal or state funded program, such as medicare or medicaid.
  • Card is accepted at over 68,000 participating pharmacies, may be used an unlimited number of times, and provides discounts on most medication.

To the Patient:

  • Simply print your ZOLPIDEM Discount Card, it works like a coupon.
  • Present your ZOLPIDEM Discount Card with your prescription to your pharmacy and you may pay less on your prescriptions.
  • On each 30-ct supply, your Discount Card may deduct from your out-of-pocket costs up to $185.**
  • Make sure to keep this Discount Card—do not leave it with the pharmacy. You will need to show your Discount Card for every prescription refill to get the savings.

To the Pharmacist:

Please use the card's BIN, PCN and Group number to adjudicate. For questions, please call 1-800-223-2146.

**Example savings are based on discounts from a prescription of ZOLPIDEM 5mg Tablet. Prices vary by pharmacy and prescription and are subject to change over time. Ask your pharmacist for the actual discounted price.

Save on your ZOLPIDEM Prescription Costs

The ZOLPIDEM Discount Card was designed to help make ZOLPIDEM prescriptions more affordable for patients. Below are some examples of actual savings. Ask your pharmacist for your discount price.

Prescription Quantity Retail Price Discounted Price Savings
ZOLPIDEM 5mg Tablet30$193.99$8.5195.61%
ZOLPIDEM 10mg Tablet30$169.75$8.6194.93%
ZOLPIDEM ER 6.25mg Tablet30$214.09$69.8467.38%
ZOLPIDEM ER 12.5mg Tablet30$238.54$78.5867.06%
  • ZOLPIDEM 5mg Tablet
  • Retail Price for 30 Tablets: $193.99
  • With Discount Card: $8.51
  • Save 95.61%
  • ZOLPIDEM 10mg Tablet
  • Retail Price for 30 Tablets: $169.75
  • With Discount Card: $8.61
  • Save 94.93%
  • ZOLPIDEM ER 6.25mg Tablet
  • Retail Price for 30 Tablets: $214.09
  • With Discount Card: $69.84
  • Save 67.38%
  • ZOLPIDEM ER 12.5mg Tablet
  • Retail Price for 30 Tablets: $238.54
  • With Discount Card: $78.58
  • Save 67.06%



    ZOLPIDEM tartrate tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. ZOLPIDEM tartrate tablets have been shown to decrease sleep latency for up to 35 days in controlled clinical studies.

    The clinical trials performed in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.


    ZOLPIDEM tartrate is contraindicated in patients with known hypersensitivity to ZOLPIDEM tartrate or to any of the inactive ingredients in the formulation. Observed reactions include anaphylaxis and angioedema


    The dose of ZOLPIDEM tartrate tablets should be individualized.

    Dosage in adults

    The recommended dose for adults is 10 mg once daily immediately before bedtime. The total ZOLPIDEM tartrate tablets dose should not exceed 10 mg per day.

    Special Populations

    Elderly or debilitated patients may be especially sensitive to the effects of ZOLPIDEM tartrate tablets. Patients with hepatic insufficiency do not clear the drug as rapidly as normal subjects. The recommended dose of ZOLPIDEM tartrate tablets in both of these patient poulations is 5 mg once daily immediately before bedtime.

    Use with CNS depressants

    Dosage adjustment may be necessary when ZOLPIDEM tartrate tablets are combined with other CNS depressant drugs because of the potentially additive effects.


    The effect of ZOLPIDEM tartrate tablets may be slowed by ingestion with or immediately after a meal.


    Tablets are available in strengths of 5 mg and 10 mg.

    Extended release tablets are available in strengths of 6.25 mg and 12.5 mg

    Store at controlled room temperature 20-25° C (68°-77°F).

ZOLPIDEM Discount Card

Frequently Asked Questions

  • How does the ZOLPIDEM Prescription Discount Card work? is partnered with companies that negotiate discounts directly with the pharmacies. These discounts are then passed directly on to cardholders.

  • Who is eligible for the ZOLPIDEM Prescription Discount Card?

    The ZOLPIDEM Prescription Discount Card has no requirements. Unlike insurance programs, there is no income, age, pre-existing condition, deductible, or waiting period restrictions. The free discount card is designed to help patients nationwide who do not have prescription drug coverage or who have coverage but are subject to large deductibles, large co-pays, formulary limitations, dosing limitations, gaps, and/or any cash out-of-pocket expenses.

  • How much does the ZOLPIDEM Prescription Discount Card/Coupon cost?

    The ZOLPIDEM Prescription Discount Card is absolutely FREE. We provide this service to every American that wishes to save on their ZOLPIDEM prescription cost. There are no premiums or deductibles associated with this program whatsoever. The printable card/coupon is available free of charge from our website.

  • How do I use the ZOLPIDEM Prescription Discount Card?
    1. Select a pharmacy: the ZOLPIDEM Prescription Discount Card is valid at over 68,000 network pharmacy locations nationwide. In most cases, your current pharmacy will be part of our network.
    2. Submit your prescription: Present your ZOLPIDEM prescription to the pharmacist. If you need to transfer a prescription, bring your empty prescription bottle or label with you to the pharmacy.
    3. Present your ZOLPIDEM Prescription Discount Card: Your card's unique code provides the pharmacist with the appropriately discounted prescription price. The price on the prescription is based on the pharmacy's contracted agreement with and our partners.
    4. You Save: Your savings will be clear once the pharmacist enters your filled prescription into the register. Whether the lowest discount price is the ZOLPIDEM Prescription Discount Card price, your present insurance program's price, or the pharmacy's already discounted price, you are GUARANTEED to receive the LOWEST price available!
  • Which pharmacies can I go to?

    We have a constantly expanding list of over 68,000 participating major chain pharmacies and local pharmacies nationwide including CVS/Pharmacy, Walgreens, Target Pharmacy, Walmart Pharmacy, Safeway, Rite Aid, and more!

  • How can I be assured I am getting the lowest price?

    The discounted price may vary by as much as 75% depending on the pharmacy discount rate contracted with While pharmacy prices may vary from week-to-week and by the geographic location, the patient is guaranteed the lowest price available regardless of whether it is the price, your present insurance program's price, or the pharmacy's already discounted price.

ZOLPIDEM Safety Information


    Need to evaluate for co-morbid diagnoses

    Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.

    Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including ZOLPIDEM.

    Severe anaphylactic and anaphylactoid reactions

    Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including ZOLPIDEM. Some patients have had additional symptoms such as dyspnea, throat closing or nausea and vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the throat, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with ZOLPIDEM should not be rechallenged with the drug.

    Abnormal thinking and behavioral changes

    A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of sedative/hypnotics. Some of these changes may be characterized by decreased inhibition (e.g., aggressiveness and extroversion that seemed out of character), similar to effects produced by alcohol and other CNS depressants. Visual and auditory hallucinations have been reported as well as behavioral changes such as bizarre behavior, agitation and depersonalization. In controlled trials, less than 1% of adults with insomnia who received ZOLPIDEM reported hallucinations. In a clinical trial, 7.4 % of pediatric patients with insomnia associated with attention-deficit/hyperactivity disorder (ADHD), who received ZOLPIDEM reported hallucinations.

    Complex behaviors such as “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported with sedative-hypnotics, including ZOLPIDEM. These events can occur in sedative-hypnotic-naive as well as in sedative-hypnotic-experienced persons. Although behaviors such as “sleep-driving” may occur with ZOLPIDEM tartrate alone at therapeutic doses, the use of alcohol and other CNS depressants with ZOLPIDEM tartrate appears to increase the risk of such behaviors, as does the use of ZOLPIDEM tartrate at doses exceeding the maximum recommended dose. Due to the risk to the patient and the community, discontinuation of ZOLPIDEM tartrate should be strongly considered for patients who report a “sleep-driving” episode. Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with “sleep-driving”, patients usually do not remember these events. Amnesia, anxiety and other neuro-psychiatric symptoms may occur unpredictably.

    In primarily depressed patients, worsening of depression, including suicidal thoughts and actions (including completed suicides), has been reported in association with the use of sedative/hypnotics.

    It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

    Withdrawal effects

    Following the rapid dose decrease or abrupt discontinuation of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs.

    CNS depressant effects

    ZOLPIDEM tartrate, like other sedative/hypnotic drugs, have CNS-depressant effects. Due to the rapid onset of action, ZOLPIDEM tartrate should only be taken immediately prior to going to bed. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following ingestion of ZOLPIDEM tartrate. ZOLPIDEM tartrate showed additive effects when combined with alcohol and should not be taken with alcohol. Patients should also be cautioned about possible combined effects with other CNS-depressant drugs. Dosage adjustments may be necessary when ZOLPIDEM tartrate is administered with such agents because of the potentially additive effects.

    Special Populations

    Use in the elderly and/or debilitated patients

    Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended ZOLPIDEM tartrate dosage is 5 mg in such patients to decrease the possibiility of side effects. These patients should be closely monitored.

    Use in patients with concomitant illness

    Clinical experience with ZOLPIDEM tartrate in patients with concomitant systemic illness is limited. Caution is advisable in using ZOLPIDEM tartrate in patients with diseases or conditions that could affect metabolism or hemodynamic responses.

    Although studies did not reveal respiratory depressant effects at hypnotic doses of ZOLPIDEM in normal subjects or in patients with mild to moderate chronic obstructive pulmonary disease (COPD), a reduction in the Total Arousal Index together with a reduction in lowest oxygen saturation and increase in the times of oxygen desaturation below 80% and 90% was observed in patients with mild-to-moderate sleep apnea when treated with ZOLPIDEM tartrate (10 mg) when compared to placebo. Since sedative/hypnotics have the capacity to depress respiratory drive, precautions should be taken if ZOLPIDEM tartrate is prescribed to patients with compromised respiratory function. Post-marketing reports of respiratory insufficiency, most of which involved patients with pre-existing respiratory impairment, have been received. ZOLPIDEM tartrate should be used with caution in patients with sleep apnea syndrome or myasthenia gravis. Data in end-stage renal failure patients repeatedly treated with ZOLPIDEM tartrate did not demonstrate drug accumulation or alterations in pharmacokinetic parameters. No dosage adjustment in renally impaired patients is required; however, these patients should be closely monitored.

    A study in subjects with hepatic impairment did reveal prolonged elimination in this group; therefore, treatment should be initiated with 5 mg in patients with hepatic compromise, and they should be closely monitored.

    Use in patients with depression

    As with other sedative/hypnotic drugs, ZOLPIDEM tartrate should be administered with caution to patients exhibiting signs or symptoms of depression. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional over-dosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.

    Use in pediatric patients

    Safety and effectiveness of ZOLPIDEM have not been established in pediatric patients. In an 8-week study in pediatric patients (aged 6-17 years) with insomnia associated with ADHD, ZOLPIDEM did not decrease sleep latency compared to placebo. Hallucinations were reported in 7.4% of the pediatric patients who received ZOLPIDEM; none of the pediatric patients who received placebo reported hallucinations [see Use in Specific Populations (8.4)].

    Laboratory Tests

    Monitoring: There are no specific laboratory tests recommended to monitor ZOLPIDEM levels.

    Interference with laboratory tests: ZOLPIDEM is not known to interfere with commonly employed clinical laboratory tests. In addition, clinical data indicate that ZOLPIDEM does not cross-react with benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screens.


    Call your doctor right away if you notice any of these side effects:

    • Allergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing
    • Anxiety, agitation, depression, nervousness, unusual behavior, thoughts of hurting yourself
    • Seeing, hearing, or feeling things that are not there
    • Severe confusion, drowsiness, muscle weakness

    If you notice these less serious side effects, talk with your doctor:

    • Daytime drowsiness
    • Diarrhea, nausea
    • Hangover feeling
    • Headache, lightheadedness, or dizziness
    • Memory loss

    If you notice other side effects that you think are caused by this medicine, tell your doctor.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


    Controlled substance

    ZOLPIDEM tartrate is classified as a Schedule IV controlled substance by federal regulation.


    Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug effects over time. Tolerance may occur to both desired and undesired effects of drugs and may develop at different rates for different effects.

    Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, using a multidisciplinary approach, but relapse is common.

    Studies of abuse potential in former drug abusers found that the effects of single doses of ZOLPIDEM tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while ZOLPIDEM tartrate 10 mg was difficult to distinguish from placebo.

    Because persons with a history of addiction to, or abuse of, drugs or alcohol are at increased risk for misuse, abuse and addiction of ZOLPIDEM, they should be monitored carefully when receiving ZOLPIDEM or any other hypnotic.


    Physical dependence is a state of adptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.

    Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild dysphoria and insomnia to a withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, and convulsions. The following adverse eventswhich are considered to meet the DSM-III-R criteria for uncomplicated sedative/hypnotic withdrawal were reported during U.S. clinical trials following placebo substitution occurring within 48 hours following last ZOLPIDEM treatment: fatigue, nausea, flushing, lightheadedness, uncontrolled crying, emesis, stomach cramps, panic attack, nervousness, and abdominal discomfort. These reported adverse events occurred at an incidence of 1% or less. However, available data cannot provide a reliable estimate of the incidence, if any, of dependence during treatment at recommended doses. Post-marketing reports of abuse, dependence and withdrawal have been received.


    Signs and symptoms

    In postmarketing experience of overdose with ZOLPIDEM tartrate alone, or in combination with CNS-depressant agents, impairment of consciousness ranging from somnolence to coma, cardiovascular and/or respiratory compromise, and fatal outcomes have been reported.

    Recommended treatment

    General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. ZOLPIDEM's sedative hypnotic effect was shown to be reduced by flumazenil and therefore may be useful; however, flumazenil administration may contribute to the appearance of neurological symptoms (convulsions). As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Hypotension and CNS depression should be monitored and treated by appropriate medical intervention. Sedating drugs should be withheld following ZOLPIDEM overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with renal failure receiving therapeutic doses have demonstrated that ZOLPIDEM is not dialyzable.

    As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.